Interferon inhibitor in the blood of patients with systemic lupus erythematosus.
Systemic lupus erythematosus (SLE) patients at advanced stages of the disease have an interferon inhibitor in the blood circulation. This inhibitor can block antiviral activity of all three types of human interferons and can significantly reduce the synthesis of interferon alpha by the treated lymphocytes obtained from normal healthy individuals. Available evidence suggests that inhibitor activity is neither because of the antibody to interferon nor due to high level of protease-like activity in the plasma. The inhibitor has also been shown to be effective in eliminating the interferon-mediated enhancement of natural killer cell activity. Interferon inhibitory activity was not detected in any of the sera taken from normal healthy individuals. Identification and characterization of interferon inhibitor has direct bearing upon effective utilization of interferons in the clinic.
Chadha
K C
KC
Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, Buffalo, NY.
Ambrus
J L
JL
Stadler
I
I
Ambrus
J L
JL
D000818:Animals; D002850:Chromatography, Gel; D005347:Fibroblasts / Q000276:immunology; D006801:Humans; D007370:Interferon Type I / Q000037:antagonists & inhibitors / Q000097:blood; D007372:Interferons / Q000037:antagonists & inhibitors* / Q000097:blood; D007694:Killer Cells, Natural / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000097:blood*; D008214:Lymphocytes / Q000276:immunology; D010222:Parainfluenza Virus 1, Human / Q000254:growth & development; D011480:Protease Inhibitors
D007370:Interferon Type I; D011480:Protease Inhibitors; D007372:Interferons